ImmRx meets neuroblastoma endpoint

Researchers from the Children's Oncology Group stopped randomization in the Phase III ANBL0032 trial in 226 children with high-risk neuroblastoma after ImmRx immunotherapy plus isotretinoin produced significantly higher event-free survival compared to isotretinoin alone after a median follow-up of 2.1 years (66% vs. 46%, p=0.0115). Preliminary data on the secondary endpoint of overall survival also was significantly higher for ImmRx patients at two years compared to isotretinoin alone (86% vs. 75%, p=0.0223). ...